ClinicalTrials.gg
Not yet recruitingNCT06212570Updated Nov 10, 2026

KeyScope Study in Uganda

An interventional study of KeySuite in Abdominal Neoplasm, sponsored by Duke University. Not yet recruiting at 1 site in Uganda. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Duke University · Not applicable, Interventional, and Diagnostic

Updated Nov 10, 2026Start date movedStudy completion movedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Sex
All
01

Study summary

KeyScope and KeyLoop (collectively called KeySuite) are laparoscopic prototypes that the investigators have designed for the resources, needs and challenges of low- and middle- income countries (LMICs). KeyScope is a laparoscope that plugs into a laptop computer to display images during surgery. It links to a telementoring application so that experienced surgeons can mentor surgeons in capacity-building partnerships. KeyLoop is a laparoscopic retractor that lifts the abdominal wall during surgery, obviating the need for a constant power supply and medical-grade carbon dioxide.

The investigators will perform a clinical First-in-Human study at the Uganda Cancer Institute. Ugandan surgeons will use the KeySuite devices to perform biopsies of intra-abdominal tumors.

02

Conditions studied

  • Abdominal Neoplasm

Browse trials for

03

In context

Abdominal Neoplasms

42 studies on the registry are indexed under Abdominal Neoplasms; 14 are open to participants now.

This study's planned enrollment of 12 is below the median of 78 across 26 interventional studies indexed under Abdominal Neoplasms.

Browse Abdominal Neoplasms studies →

Lead sponsor

Duke University is the lead sponsor of 2,063 studies on the registry; 273 are open to participants now.

Of its 204 completed or terminated interventional studies of FDA-regulated products, 167 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of intra-abdominal mass suspicious for cancer
  • (BMI) of 18-30
  • weight 20-100kg
  • necessary to determine cancer diagnosis and classify pathology
  • surgeon determine that laproscopic biopsy it technically appropriate

Exclusion criteria

Exclusion Criteria:

  • significant comorbidities
  • previous major abdominal surgery
  • current pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    KeySuite

    The KeyLoop and KeyScope devices will be used to perform intra-abdominal biopsies.

    Device: KeySuite

Interventions

  • DeviceKeySuite

    KeyScope and KeyLoop will be used to perform biopsies of intra-abdominal masses and cancers.

06

What researchers measure

Primary outcomes

  1. Establish the clinical safety KeySuite

    This will be determined by whether or not the procedure was able to be completed laproscopically or had to be converted to open surgery.

    Time frame: Day of surgery

Secondary outcomes

  1. Time to complete surgery

    Length of surgery will be recorded

    Time frame: Day of surgery

  2. Estimated blood loss

    Blood loss will be recorded

    Time frame: Day of surgery

  3. Surgical injuries and adverse events

    Surgical injuries (device-related and unrelated) and other adverse events at the time of surgery will be recorded

    Time frame: Day of surgery

Other outcomes

  1. Surgical site infection

    Any infections at the surgical site will be recorded and followed until resolution

    Time frame: 30 days

  2. Post-operative complications

    All post-operative complications will be recorded

    Time frame: 30 days

  3. Mortality

    Survival through 30 days

    Time frame: 30 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Start date
Sep 1, 2026→Jan 1, 2027
Nov 10, 2026
Study completion
Jun 30, 2028→Dec 30, 2027
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Start date Sep 1, 2026→Jan 1, 2027
    Study completion Jun 30, 2028→Dec 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06212570
Lead sponsor
Duke University
Collaborators
Makerere University, Uganda Cancer Institute
Responsible party
Sponsor
First posted
Jan 19, 2024
Start date
Jan 1, 2027 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Tamara Fitzgerald, MD, PhD
Contact
tamara.fitzgerald@duke.edu
919-681-5077
Dana Giangiacomo
Contact
dana.giangiacomo@duke.edu
919-684-3821
Tamara Fitzgerald, MD, PhD
principal investigator · Duke Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion